Clinical Trial Update: Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study of blinatumomab in adults with newly diagnosed high-risk diffuse large B-cell lymphoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Blinatumomab (blinatumomab)

Snippet

Sponsor: Amgen | Conditions: High-risk Diffuse Large B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-03-26